Efficacy and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer and Autoimmune Diseases
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Autoimmune diseases (AIDs) in non-small cell lung cancer (NSCLC) patients show potential benefit from immune checkpoint inhibitors (ICIs). Careful monitoring is crucial due to risks of immune-related adverse events and AID exacerbation.
Area Of Science
- Oncology
- Immunology
- Rheumatology
Background
- Autoimmune diseases (AIDs) are increasingly recognized as a comorbidity in lung cancer patients.
- The clinical characteristics and treatment outcomes for non-small cell lung cancer (NSCLC) in the context of AIDs are not well-defined.
- Understanding these associations is critical for optimizing patient care.
Purpose Of The Study
- To investigate the clinical features of NSCLC in patients with co-existing AIDs.
- To evaluate the efficacy and safety of treatments, including immune checkpoint inhibitors (ICIs), in this specific patient population.
Main Methods
- A retrospective observational study was conducted at a single center.
- Data were collected from June 2016 to October 2024, including patients with primary NSCLC and diagnosed AIDs.
- Treatment outcomes, adverse events, and survival data were analyzed.
Main Results
- Thirty-two patients were analyzed, with rheumatoid arthritis being the most common AID.
- Immune checkpoint inhibitors (ICIs) showed a response rate of 63.6%, but 72.7% experienced immune-related adverse events (irAEs), with 45.5% experiencing AID exacerbation.
- Patients without driver mutations receiving ICIs had significantly longer overall survival (OS) compared to those with driver mutations (2,274 vs. 654 days).
- Good performance status, adenocarcinoma, and ICI administration were linked to better OS.
Conclusions
- Immune checkpoint inhibitors (ICIs) may offer therapeutic benefits for select NSCLC patients with AIDs.
- Close monitoring for irAEs and potential exacerbation of underlying AIDs is essential when using ICIs.
- Further research is warranted to refine treatment strategies for this complex patient group.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...